Hot Picks: Biotech rebound turns to rare disease catalysts [BNN Bloomberg (Canada)]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: BNN Bloomberg
next year as investors weigh clinical risk, regulation and capital discipline. Analysts say rare disease programs with differentiated profiles and near-term catalysts may stand out as markets grow more selective. BNN Bloomberg spoke with Laura Chico, managing director in equity research at Wedbush Securities, about several biotech companies she says are supported by upcoming clinical data, regulatory decisions and longer-term opportunities in underserved patient populations. Key Takeaways The biotech sector's strong 2025 recovery has shifted investor attention to whether catalyst momentum can continue into 2026. Rare disease indications remain attractive due to high unmet need, pricing power and relatively defined patient populations. Investors are increasingly focused on late-stage clinical data and regulatory decisions as key drivers of valuation re-ratings. Safety profiles and ease of administration are emerging as critical differentiators in competitive therapeutic mar
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wells Fargo & Company from $26.00 to $29.00. They now have an "equal weight" rating on the stock.MarketBeat
- Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- Viridian Therapeutics (NASDAQ:VRDN) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.MarketBeat
VRDN
Earnings
- 2/27/25 - Beat
VRDN
Sec Filings
- 1/2/26 - Form 4
- 12/31/25 - Form 144
- 11/14/25 - Form SCHEDULE
- VRDN's page on the SEC website